The primary purpose of this thirteen-week, open-label study is to test the hypothesis that quetiapine in combination with Oros methylphenidate will reduce aggressive symptoms in children and adolescents who have shown inadequate response to OROS methylphenidate alone.

Informed consent will be obtained from the subject and parent or legal guardian before any study procedures begin. Study procedures will include the verification of inclusion and exclusion criteria, and completion of assessments and safety measures (physical examination, vital signs, adverse events and concomitant medication review, AIMS, laboratory tests, ECG, pregnancy test) as indicated in the Schedule of Events. All laboratory and electrocardiogram results must be reviewed by a physician before the subject returns for Visit 2.

Study Period II (Visits 2-5)

All subjects meeting entry criteria will initially receive Oros methylphenidate beginning at Visit 2. The Oros methylphenidate will be titrated over 3 visits according to the following schedule:

• Visit 2 dose of 18 mg QAM
• Visit 3 dose of 36mg QAM
• Visit 4 dose of 54mg QAM.
• At Visit 5, any subjects unable to tolerate continuation of the Oros methylphenidate dose of 54mg QAM or subjects that meet improvement criteria as defined above will be discontinued from the study. Subjects able to tolerate the daily dose of 54mg Oros methylphenidate and who do not meet improvement criteria at Visit 5 will begin receiving quetiapine in addition to continuing Oros methylphenidate at 54mg QAM for the balance of the study. The initial dose of quetiapine dispensed at Visit 5 will be 25mg QAM for one day with an increase to 25mg BID until Visit 6.

At each visit safety and efficacy information will be completed according to the Schedule of Events.

Study Period III (Visits 6-10) Quetiapine will be titrated at Visits 6 - 9 according to the parameters in the quetiapine dosing schedule and the completion of safety and efficacy measures listed in the Schedule of Events. A telephone follow-up with the parent or legal guardian will be made 7-9 days after Visit 8 for physician review of subject adverse events and safety.

At visit 10 subjects will be given clinical recommendations for follow-up care from a physician investigator after completion of all study procedures (labs/EKG, vital signs, physical exam, AIMS, ADHD-RS-IV, CGI-I, CGI-S, RAAPP, MOAS, SNAP, CCPT)

Inclusion Criteria:

1. Subjects must be at least 12 yrs.old but less than 18 when informed consent is obtained.

2. Subjects must meet DSM-IV criteria for ADHD/Combined Type and one of the Disruptive Behavior Disorders as diagnosed by clinical interview and confirmed by the Kiddie-SADS-PL (K-SADS-PL) semistructured diagnostic interview.

3. Subjects must have one DSM-IV aggressive feature of Conduct Disorder (CD) as rated on the K-SADS-PL including:

   • initiation of physical fights (CD symptom A2)
   • use of a weapon to bring harm to others (CD symptom A3)
   • physical cruelty to people (CD symptom A4) or animals (CD symptom A5)
   • confrontation stealing (CD symptom A6)
   • destruction of property (CD symptom A8 or A9).

4. Subjects must have severe aggressive and ADHD symptoms as indicated by a global CGI score of 4 or greater and a RAAPP score of 4 or 5 at Visit 1.

5. Subjects must have had at least four outbursts per month involving destruction of property, verbal aggression, or physical aggression toward others or self during the past two months at Visit 1.

6. Subjects with previous trials of psychostimulants must have had a response insufficient to markedly change overall quality of life as defined by a CGI score of 3 or greater based on interview with the parent.

7. Subjects must not have taken any medication for the treatment of ADHD or DBD for either 5 half-lives of the medication or 28 days (whichever is less) at Visit 1. If subjects are currently taking medications for the treatment of ADHD or DBD, the assent and consent must be reviewed and signed by the subject and parent/legal guardians (Visit 0) before the physician investigator will provide a tapering schedule for current medications.

8. Laboratory results obtained at Visit 1 must be reviewed by a physician by Visit 2 and show no significant abnormalities.

9. Baseline electrocardiogram (ECG) results obtained at Visit 1 must be assessed by a physician by Visit 2 and show no significant abnormalities.

Exclusion Criteria:

1. Subjects with likely mental retardation as defined as a K-BIT Matrices IQ score of less than 70 at Visit 1.

2. Subjects who meet criteria for bipolar disorder as diagnosed by clinical interview and confirmed by the K-SADS-PL at Visit 1.

3. Subjects with a biological parent or sibling who meets criteria for bipolar disorder.

4. Subjects who have any history of psychosis.

5. Subjects who weigh less than 30kg or more than 80kg at study entry.

6. Female subjects who are pregnant or who are breast-feeding as assessed at Visit 1.

   Postmenarcheal sexually-active females who are not using a clinically acceptable method of birth control.

7. Subjects with a history of any seizure disorder other than febrile seizures.

8. Subjects with a history of alcohol or drug abuse within the past three months or who are currently using alcohol, drugs of abuse, or any prescribed or over-the-counter medications in a manner considered abusive by the investigators.

9. Subjects currently taking any psychotropic medications or who are likely to need psychotropic medications during the study as assessed by the physician at Visit 1.

10. Subjects considered to be at serious suicidal risk.

11. Subjects taking any medications that are not reviewed and approved by a physician investigator. Specific requirements include:

    • Psychotropic medications other than quetiapine and Concerta may not be used during the trial.
    • Patients may receive lorazepam or chlorpromazine if needed for severe aggression. These drugs should not be given beyond 24 hours.

There were no unanticipated limitations/caveats. All of the typical caveats of open-label studies apply: As a result, bias, placebo effects, demand characteristics, and other non-treatment related effects may have contributed to results.